<DOC>
	<DOCNO>NCT00072488</DOCNO>
	<brief_summary>RATIONALE : New image procedure , whole-body MRI , may improve ability detect metastatic cancer determine extent disease . PURPOSE : This clinical trial study whole-body MRI see well work compare standard imaging procedure detect distant metastasis patient solid tumor lymphoma .</brief_summary>
	<brief_title>Whole-Body MRI Conventional Imaging Detecting Distant Metastases Young Patients With Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare non-inferior diagnostic performance whole-body MRI ( i.e. , combination turbo short-tau inversion-recovery ( STIR ) out-of-phase image ) v conventional imaging ( i.e. , combination chest CT scan , scintigraphy [ bone , gallium , meta-iodobenzylguanidine ( MIBG ) , optional fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) ] abdominal/pelvic CT scan/MRI indicate ) detect distant metastasis use stag common tumor pediatric patient . Secondary - Determine incremental benefit add out-of-phase T1-weighted gradient-recalled echo image turbo STIR detect distant disease patient . - Determine , preliminarily , relative accuracy FDG-PET , whole-body MRI , combination FDG-PET whole-body MRI detecting stage IV disease patient . - Determine effect multiple factor , include cancer type , site primary tumor , patient age , diagnostic accuracy whole-body MRI patient . - Determine interobserver variability associate interpret whole-body MRI exams detect distant metastasis patient . OUTLINE : This multicenter study . Patients undergo conventional MRI , CT scan , and/or scintigraphy ( e.g. , bone , meta-iodobenzylguanidine [ MIBG ] , gallium ) experimental whole-body MRI sequence . Patients may optionally undergo fludeoxyglucose F18 positron emission tomography ( FDG-PET ) . Patients lesion ( lesion ) detect whole-body MRI FDG-PET initial staging confirm biopsy conventional imaging study stag repeat standard image 3- 6-month follow-up . Patients abnormality consider highly suspicious metastasis biopsy proof metastasis obtain receive treatment discretion treat physician . Patients follow annually 3 year . PROJECTED ACCRUAL : A total 226 patient ( 45 neuroblastoma , 54 rhabdomyosarcoma , 27 sarcoma , 100 lymphoma ) accrue study within 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis OR newly diagnose mass strongly suspect represent 1 follow : Rhabdomyosarcoma Ewing 's sarcoma family tumor Neuroblastoma Hodgkin 's lymphoma NonHodgkin 's lymphoma All imaging examination ( e.g. , CT scan , MRI , scintigraphy ) must perform within 14 day within 2 month diagnostic operative procedure Whole body MRI positron emission tomography ( PET ) scanning ( PET scan do ) must do treatment Prior CT scan , conventional MRI , bone scintigraphy , gallium scintigraphy , metaiodobenzylguanidine ( MIBG ) scintigraphy perform outside institution allow provided technical standard specify study practice Bone scintigraphy require patient neuroblastoma , rhabdomyosarcoma , sarcomas Gallium scintigraphy require lymphoma patient PET scan perform No CNS primary tumor PATIENT CHARACTERISTICS : Age 21 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No active cardiac pacemaker Other Not pregnant nursing No prior malignancy No uncontrolled diabetes mellitus ( patient undergo optional PET ) Patients control diabetes mellitus must fast blood glucose great 200 mg/dL No contraindication MRI CT scan ( e.g. , intracranial vascular clip ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Prior biopsy surgery allow provide 2 month pass since procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>localize Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
</DOC>